US Patent Issued to Novartis on June 9 for "Methods for treating diabetic retinopathy using brolucizumab" (Swiss Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,649,781, issued on June 9, was assigned to Novartis AG (Basel, Switzerland).

"Methods for treating diabetic retinopathy using brolucizumab" was invented by Margarita Gekkieva (Basel, Switzerland) and Philippe Maria Clotaire Margaron (Reinach, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method is provided for treating a patient having a neovascular ocular disease."

The patent was filed on Sept. 11, 2020, under Application No. 17/641,799.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1...